# US 2025/0147045 A1 · Biomarker panels and methods for predicting preeclampsia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0147045 A1
- Document ID: US20250147045A1
- Status: Published application
- Kind: A1
- Application number: 18/730,661
- Filed: 2022-08-15
- Published: 2025-05-08
- Earliest claimed: 2022-02-18
- Assignees: Sera Prognostics, Inc.
- Applicants: Sera Prognostics, Inc.
- Inventors: Julja Burchard; Paul Edward Kearney; Md Bahadur Badsha; Ashoka Dharmapriya Polpitiya
- Web page: https://patentgrep.com/patent/US20250147045A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female, including preterm preeclampsia or preeclampsia at any gestational age. The disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing, in the future, or presently suffering from, preeclampsia relative to matched controls. The disclosure is also partially based on the unexpected discovery that panels combining one or more of these proteins/peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia, either individually or in a panel of biomarkers.

## Claims

### Claim 1

A panel of isolated biomarkers comprising N of the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 2 (depends on 1)

The panel of claim 1, wherein Nis a number selected from the group consisting of 2 to 12.

### Claim 3 (depends on 2)

The panel of claim 2, wherein said panel comprises at least two, at least three, or at least four of the isolated biomarkers selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 4 (depends on 2)

The panel of claim 2, wherein said panel comprises at least two, at least three, or at least four isolated biomarkers selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.

### Claim 5 (depends on 2)

The panel of claim 2, wherein said panel comprises at least three isolated biomarkers selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.

### Claim 6

A method of determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, the method comprising detecting a measurable feature of each of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9 in a biological sample obtained from said pregnant female, and analyzing said measurable features to determine the probability for preterm preeclampsia or preeclampsia at any gestational age in said pregnant female.

### Claim 7 (depends on 6)

The method of claim 6, wherein said measurable feature comprises fragments or derivatives of each of said N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein said detecting a measurable feature comprises quantifying an amount of each of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9, combinations or portions and/or derivatives thereof in a biological sample obtained from said pregnant female.

### Claim 9 (depends on 8)

The method of claim 8, further comprising calculating the probability for preterm preeclampsia or preeclampsia at any gestational age in said pregnant female based on said quantified amount of each of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 10 (depends on 6, 7, 8, 9)

The method of any one of claims 6-9, further comprising an initial step of providing a biomarker panel comprising N of the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 11 (depends on 6, 7, 8, 9)

The method of any one of claims 6-9, further comprising an initial step of providing a biological sample from the pregnant female.

### Claim 12 (depends on 6, 7, 8, 9, 10, 11)

The method of any one of claims 6-11, further comprising communicating said probability to a health care provider.

### Claim 13 (depends on 12)

The method of claim 12, wherein said communication informs a subsequent treatment decision for said pregnant female.

### Claim 14 (depends on 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 6-13, wherein N is a number selected from the group consisting of 2 to 12.

### Claim 15 (depends on 14)

The method of claim 14, wherein said N biomarkers comprise at least two, at least three, or at least four of the isolated biomarkers selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 16 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 6-15, wherein said analysis comprises a use of a predictive model.

### Claim 17 (depends on 16)

The method of claim 16, wherein said analysis comprises comparing said measurable feature with a reference feature.

### Claim 18 (depends on 17)

The method of claim 17, wherein said analysis comprises using one or more selected from the group consisting of a linear discriminant analysis model, a support vector machine classification algorithm, a recursive feature elimination model, a prediction analysis of microarray model, a logistic regression model, a CART algorithm, a flex tree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, a machine learning algorithm, a penalized regression method, and a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein said analysis comprises logistic regression.

### Claim 20 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 6-19, wherein said probability is expressed as a risk score.

### Claim 21 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 6-20, wherein the biological sample is selected from the group consisting of whole blood, plasma, and serum.

### Claim 22 (depends on 21)

The method of claim 21, wherein the biological sample is serum.

### Claim 23 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 6-22, wherein said quantifying comprises mass spectrometry (MS).

### Claim 24 (depends on 23)

The method of claim 23, wherein said MS comprises liquid chromatography-mass spectrometry (LC-MS).

### Claim 25 (depends on 23)

The method of claim 23, wherein said MS comprises multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).

### Claim 26 (depends on 25)

The method of claim 25, wherein said MRM comprises scheduled MRM or said SRM comprises scheduled SRM.

### Claim 27 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 6-26, wherein said quantifying comprises an assay that utilizes a capture agent.

### Claim 28 (depends on 27)

The method of claim 27, wherein said capture agent is selected from the group consisting of and antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein said assay is selected from the group consisting of enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA).

### Claim 30 (depends on 29)

The method of claim 29, wherein said quantifying further comprises mass spectrometry (MS).

### Claim 31 (depends on 30)

The method of claim 30, wherein said quantifying comprises co-immunoprecipitation-mass spectrometry (co-IP MS).

### Claim 32 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 6-31, further comprising detecting a measurable feature for one or more risk indicia.

### Claim 33 (depends on 32)

The method of claim 32, wherein the one or more risk indicia are selected from the group consisting of history of preterm preeclampsia, severe preeclampsia, preeclampsia at any gestational age, first pregnancy, age, obesity, diabetes, gestational diabetes, hypertension, kidney disease, multiple pregnancy, interval between pregnancies, new paternity, migraine headaches, rheumatoid arthritis, and lupus.

### Claim 34

A method of determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, the method comprising: (a) quantifying in a biological sample obtained from said pregnant female an amount of each of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9; (b) multiplying said amount by a predetermined coefficient, (c) determining the probability for preterm preeclampsia or preeclampsia at any gestational age in said pregnant female comprising adding said individual products to obtain a total risk score that corresponds to said probability.

### Claim 35 (depends on 2)

The panel of claim 2, wherein said panel comprises at least two, at least three, or at least four isolated biomarkers selected from the group consisting of
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG); and
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 36 (depends on 6)

The method of claim 6, wherein said N biomarkers comprise at least two, at least three, or at least four of the isolated biomarkers selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 37 (depends on 34)

The method of claim 34 wherein said N biomarkers comprise at least two, at least three, or at least four of the isolated biomarkers selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 38 (depends on 34)

The method of claim 34, herein said N biomarkers comprise at least two, at least three, or at least four isolated biomarkers selected from the group consisting of
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG);
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 39 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38)

The method of any one of claim 6-34 or 36-38, wherein the method is for determining probability for preterm preeclampsia in a pregnant female.

### Claim 40 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38)

The method of any one of claim 6-34 or 36-38, wherein the is method for determining probability for preeclampsia at any gestational age in a pregnant female.

### Claim 41

A kit comprising one or more agents for detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, CBPN, CSH and SHBG.

### Claim 42

A kit comprising one or more agents for detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 43 (depends on 42)

The kit of claim 42, wherein the one or more biomarkers are selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 44 (depends on 42)

The kit of claim 42, wherein the one or more biomarkers comprise at least two, at least three, or at least four isolated biomarkers selected from the group consisting of:
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG);
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 45 (depends on 41, 42, 43, 44)

The kit of any one of claims 41 to 44, wherein the kit is for use in determining probability for preterm preeclampsia in a pregnant female.

### Claim 46 (depends on 41, 42, 43, 44)

The kit of any one of claims 41 to 44, wherein the kit is for use in determining probability for preeclampsia at any gestational age in a pregnant female.

### Claim 47

A biochip for the detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, CBPN, CSH and SHBG.

### Claim 48

A biochip for the detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 49 (depends on 48)

The biochip of claim 48, wherein the one or more biomarkers are selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 50 (depends on 48)

The biochip of claim 48, wherein the one or more biomarkers comprise at least two, at least three, or at least four isolated biomarkers selected from the group consisting of:
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG);
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 51 (depends on 47, 48, 49, 50)

The biochip of any one of claims 47 to 50, wherein the biochip is for use in determining probability for preterm preeclampsia in a pregnant female.

### Claim 52 (depends on 47, 48, 49, 50)

The biochip of any one of claims 47 to 50, wherein the biochip is for use in determining probability for preeclampsia at any gestational age in a pregnant female.

### Claim 53

A biomarker for use in determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein the biomarker is selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.

### Claim 54

A biomarker for use in determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein the biomarker is from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.

### Claim 55 (depends on 54)

The biomarker of claim 54, wherein the biomarker is selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 56 (depends on 54)

The biomarker of claim 54, wherein the biomarker is selected from the group consisting of:
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG);
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 57 (depends on 53, 54, 55, 56)

The biomarker of any one of claims 53 to 56, wherein the biomarker is for use in determining probability for preterm preeclampsia in a pregnant female.

### Claim 58 (depends on 53, 54, 55, 56)

The biomarker of any one of claims 53 to 56, wherein the biomarker is for use in determining probability for preeclampsia at any gestational age in a pregnant female.

### Claim 59

Use of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and/or the ratio of IBP4 levels to SHBG levels, as a biomarker or biomarkers for determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female.

### Claim 60

Use of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9 for determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein N is a number selected from the group consisting of 2 to 12.

### Claim 61 (depends on 60)

The use of claim 60, wherein said N biomarkers comprise at least two, at least three, or at least four of the isolated biomarkers selected from the group consisting of the exemplary peptides listed in Table 1.

### Claim 62 (depends on 60)

The use of claim 60, wherein said N biomarkers comprise at least two, at least three, or at least four isolated biomarkers selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.

### Claim 63 (depends on 60)

The use of claim 60, wherein said N biomarkers comprise at least three isolated biomarkers selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.

### Claim 64 (depends on 60)

The use of claim 60, wherein said N biomarkers comprise at least two, at least three, or at least four isolated biomarkers selected from the group consisting of:
(a) Monocyte differentiation antigen CD14 (CD14);
(b) L-selectin (LYAM1);
(c) Insulin-like growth factor-binding protein 4 (IBP4);
(d) Inhibin beta C chain (INHBC);
(e) Bone marrow proteoglycan (PRG2);
(f) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2);
(g) Pigment epithelium-derived factor (PEDF);
(h) Pappalysin-1 (PAPP1);
(i) Sex hormone-binding globulin (SHBG);
(j) Afamin (AFAM);
(k) Carboxypeptidase N catalytic chain (CBPN); and
(l) Chorionic Somatomammotropin Hormone 1 and 2 (CSH).

### Claim 65 (depends on 59, 60, 61, 62, 63, 64)

The use of any one of claims 59 to 64, wherein the use is for determining probability for preterm preeclampsia in a pregnant female.

### Claim 66 (depends on 59, 60, 61, 62, 63, 64)

The use of any one of claims 59 to 64, wherein the use is for determining probability for preeclampsia at any gestational age in a pregnant female.

### Claim 67 (depends on 1, 2, 3, 4, 5, 35)

The panel of any one of claim 1-5 or 35, wherein the panel is for use in determining probability for preterm preeclampsia in a pregnant female.

### Claim 68 (depends on 1, 2, 3, 4, 5, 35)

The panel of any one of claim 1-5 or 35, wherein the panel is for use in determining probability for preeclampsia at any gestational age in a pregnant female.
